Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Resistance to immune checkpoint blockade in patients with cSCC

Paolo Bossi • 5 Jun 2022
ASCO 2022
Skin Cancer Antibodies Cetuximab Pembrolizumab
I-Tackle

Paolo Bossi, MD, University of Brescia, Brescia, Italy, discusses the development of resistance to immunotherapy in patients with primary cutaneous squamous cell carcinomas (cSCC), highlighting the clinical and molecular significance. Dr Bossi speaks on the Phase II I-TACKLE trial (NCT03666325) of pembrolizumab and cetuximab in patients with locally advanced/metastatic cSCC, which aims to tackle the development of resistance to immune checkpoint blockade. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Paolo Bossi

The future role of immunotherapy in head and neck cancer
1:37
The future role of immunotherapy in head and neck cancer
Paolo Bossi • 27 Mar 2023
HPV status, artificial intelligence, and IO in head and neck cancer
2:09
HPV status, artificial intelligence, and IO in head and neck cancer
Paolo Bossi • 27 Mar 2023
The role of quality of life in the management of head and neck cancer
4:29
The role of quality of life in the management of head and neck cancer
Paolo Bossi • 27 Mar 2023
Reducing oral mucositis in patients treated with CRT using avasopasem manganese
1:25
Reducing oral mucositis in patients treated with CRT using avasopasem manganese
Paolo Bossi • 5 Jun 2022

Related Videos

BRAF/MEK inhibition prior to immunotherapy in melanoma: insights from the COWBOY trial
1:45
BRAF/MEK inhibition prior to immunotherapy in melanoma: insights from the COWBOY trial
Kalijn Bol • 31 May 2026
COWBOY trial: optimal sequencing of BRAF/MEK inhibition and immunotherapy in BRAF-mutated melanoma
1:08
COWBOY trial: optimal sequencing of BRAF/MEK inhibition and immunotherapy in BRAF-mutated melanoma
Kalijn Bol • 31 May 2026
Could induction BRAF/MEK inhibition be useful for some melanoma patients with metastases?
1:02
Could induction BRAF/MEK inhibition be useful for some melanoma patients with metastases?
Kalijn Bol • 31 May 2026
The future of personalized and off-the-shelf mRNA vaccines in melanoma
1:02
The future of personalized and off-the-shelf mRNA vaccines in melanoma
James Smithy • 31 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals